medicalmeds.eu Medicines The immunostimulating drug. Not OVIR

Not OVIR

Препарат Неовир. ОАО "Фармсинтез" Россия

Producer: JSC Pharmsintez Russia

Code of automatic telephone exchange: L03AX

Release form: Liquid dosage forms. Solution for injections.

Indications to use: Flu. Cytomegaloviral infection. HIV infection. Encephalitis. Chronic hepatitis. Venereal lymphogranuloma. Acute hepatitis. Urethritis. Multiple sclerosis. Skin candidiasis. Candidiasis of mucous membranes. Virus of papilloma of the person (Papillomavirusnaya infektsiiya). Immunodeficiency.

General characteristics. Structure:

Active component: oxodihydroacridinylsodium acetate (Неовир®) — 125 mg.

Excipients: sodium citrate — 2,5 mg; citric acid monohydrate — 0,5–1,5 mg (to pH 7,5–8,3); water for injections — to 1 ml.

Pharmacological properties:

Pharmacodynamics. Drug possesses antiviral action concerning DNA and RNA-genomic viruses. Possesses the expressed anti-Chlamidia action. Неовир® causes bystry increase of credits of endogenous interferon and, р, at, in particular interferon and. Introduction of 250 mg of Neovira® intramusculary on the revealed serumal concentration of interferon is equivalent to introduction of 6-9 million ME of recombinant interferon and. The peak of activity of interferon in blood is observed in 1,5–2 hours and remains within 16–20 hours after introduction of Neovira®. As a result in an organism the cascade of the immune responses directed to destruction and elimination of activators and the cells struck with them is induced. Cells — producers of interferon gain ability to the strengthened production of interferon in response to the repeated induction caused by the pathological agent. This property remains a long time after drug withdrawal.

Immunomodulatory action is caused by ability of Neovira® to activate stem hemopoietic cells, to normalize balance of subpopulations of T lymphocytes, to stimulate effector links of immune system. Неовир® renders the expressed stimulating effect on functional activity of macrophages and polymorphonuclear leukocytes, strengthening their migration and phagocytal activity. Неовир® adjusts fabric growth: activates NK cells, strengthens all forms of cytotoxicity, positively influences recovery of adhesiveness of cells, inhibits their proliferative and metastatic activity.

Pharmacokinetics. At intramuscular introduction bioavailability of Neovira® makes more than 90%. After introduction of 100-500 mg of Neovira® the maximum concentration in plasma is reached in 15–30 min. and makes 8,3 mkg/ml. In 5 hours only insignificant quantities of Neovira® are defined, in 6 hours Neovir® in a blood plasma is not found. Неовир® it is allocated from an organism in not changed look with kidneys, without being exposed to metabolism, with an elimination half-life 1 hour. In 15–30 min. after introduction of Neovira® in plasma credits of endogenous interferon, in particular early interferon begin to accrue and. 2 peaks of content of interferon and in plasma are revealed: 70 ME/ml in 1,5–2 hours and 110 ME/ml in 8–10 hours then the content of interferon and begins to decrease. In 24 hours concentration of endogenous interferon remains rather high, to reference values is returned in 46–48 hours after introduction.

Indications to use:

Treatment (as a part of complex therapy):
-   flu and other acute respiratory viral diseases, including against the background of immunodeficiency;
-   the infections caused by the virus Herpes simplex, Varicella zooster, Herpes simplex genitalis including at persons with disturbances of immune system;
-   a Cytomegaloviral infection at persons with an immunodeficiency;
-   radiation immunodeficiency;
-   HIV infection;
-   encephalitis and encephalomyelitis of a virus etiology;
-   acute and chronic hepatitises B and C;
-   uretrit, epididymites, prostatitises, tservitsit and salpingites of a Chlamidia etiology;
-   venereal lymphogranuloma;
-   oncological diseases;
-   multiple sclerosis;
-   candidosis damages of skin and mucous membranes;
-   human papillomavirus infection.
Prevention of flu and other acute respiratory viral diseases.

Route of administration and doses:

Solution for injections is entered intramusculary, the single therapeutic dose makes 250 mg (1 ampoule) or 4–6 mg on kg of body weight of the patient. If necessary the single dose of the drug Neovir® can be increased to 500 mg. The course of treatment if there are no special instructions, consists of 5–7 intramuscular injections of Neovira® in a dose of 250 mg with an interval of 48 hours, the course dose depends on a clinical picture. Duration of a course is 8–12 days. The single preventive dose makes 250 mg (1 ampoule) or 4–6 mg on body weight kg. At prolonged use the recommended interval between introductions of Неовира® 3-7 days. At HIV infection Neovira® solution to injections is applied in a combination with specific antiviral drugs. The course of treatment consists of 10 injections on 250 mg with an interval between injections of 48 hours. After a course 2 months do a break. Use of repeated courses according to indications is possible.

Features of use:

Information on a possibility of negative influence of drug on performance of potentially dangerous types of activity requiring special attention and bystry reactions (driving and other vehicles, work with moving mechanisms, work of the dispatcher and operator, etc.) is absent.

Side effects:

In isolated cases emergence of allergic reaction in the form of an enanthesis is possible. Subfebrile temperature, the local quickly passing morbidity in a drug injection site are possible. At bad portability or morbidity in an injection site it is recommended to enter Neovir® together with solution of local anesthetic (2 ml of 0,25-0,5% of solution of Procainum).

Interaction with other medicines:

During clinical trials and use in clinical practice cases of incompatibility or potentiation of effect of drug at interaction with other medicines were not registered.

Contraindications:

Individual intolerance of drug. The expressed insufficiency of function of kidneys (clearance of creatinine less than 30 ml/min.). Autoimmune diseases. Pregnancy and a lactation, children's age up to 18 years.

Overdose:

There are no data concerning overdose of drug.

Storage conditions:

In the dry, protected from light place at a temperature from 15 to 25 °C. To store in the place, unavailable to children. Opacification of Neovira® solution till milky-white color demonstrates disturbance of storage conditions and unfitness to use.

Issue conditions:

According to the recipe

Packaging:

Solution for intramuscular introduction of 250 mg / 2 ml in ampoules of light-protective glass on 2 ml; on 3, 5 ampoules in a blister strip packaging from a film polyvinyl chloride; on 1 blister strip packaging with the instruction on a medical use in a pack from a cardboard.